Grant Life Sciences, Inc. Form NT 10-K March 31, 2006

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 12b-25

Commission File Number 000-50133

NOTIFICATION OF LATE FILING

"Form N-SAR	Form 11-K	Form 20-F	Form 10-Q	
For Period Ended: I	December 31, 2005			
"Transition Report" Transition Report			ort on Form 10-Q ort on Form N-SAR	
For the Transition F	Period Ended:	· · · · · · · · · · · · · · · · · · ·		
Nothing in this forn	n shall be construed	to imply that the Con	mmission has verified any information contained	herein.
If the notification re	elates to a portion of	the filing checked al	pove, identify the item(s) to which the notification	n

PART I REGISTRANT INFORMATION

Full name of registrant
Former name if applicable
Address of principal executive office
City, state and zip code

Grant Life Sciences, Inc.

64 East Winchester, Suite 205 Murray, Utah 84107

PART II RULE 12b-25 (b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

- T (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form 10-Q, or portion thereof will be filed on or before
 - the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

Edgar Filing: Grant Life Sciences, Inc. - Form NT 10-K

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

The registrant is in the process of preparing and reviewing the financial information of the registrant. The process of compiling and disseminating the information required to be included in the Form 10-KSB for the relevant fiscal year, as well as the completion of the required review of the registrant's financial information, could not be completed without incurring undue hardship and expense. The registrant undertakes the responsibility to file such annual report no later than fifteen days after its prescribed due date.

PART IV OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Don Rutherford (801) 261-8736 (Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

T Yes "No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

"Yes T No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Edgar Filing: Grant Life Sciences, Inc. - Form NT 10-K

Grant Life Sciences, Inc. Name of Registrant as Specified in Charter.

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 31, 2006	By: /s	s/ Don Rutherford
	D	Oon Rutherford